EUR 0.16
(-2.95%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 14.33 Million EUR | -38.41% |
2022 | 23.27 Million EUR | -13.22% |
2021 | 26.81 Million EUR | 92.33% |
2020 | 13.94 Million EUR | -11.1% |
2019 | 15.68 Million EUR | 13.14% |
2018 | 13.86 Million EUR | 39.9% |
2017 | 9.9 Million EUR | 24.77% |
2016 | 7.94 Million EUR | 156.26% |
2015 | 3.09 Million EUR | 359.78% |
2014 | 673.97 Thousand EUR | 35.25% |
2013 | 498.32 Thousand EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.19 Million EUR | 0.0% |
2024 Q1 | 2.19 Million EUR | -43.78% |
2023 Q2 | 3.52 Million EUR | 0.0% |
2023 Q3 | 4.28 Million EUR | 21.62% |
2023 FY | 15.09 Million EUR | -35.15% |
2023 Q4 | 3.9 Million EUR | -8.79% |
2023 Q1 | 3.52 Million EUR | -38.22% |
2022 Q2 | 14.38 Million EUR | 152.55% |
2022 Q1 | 5.69 Million EUR | -68.83% |
2022 FY | 23.27 Million EUR | -13.22% |
2022 Q3 | 5.69 Million EUR | -60.4% |
2022 Q4 | 5.69 Million EUR | 0.0% |
2021 Q4 | 18.27 Million EUR | 108.87% |
2021 FY | 26.81 Million EUR | 92.33% |
2021 Q1 | 6.5 Million EUR | -17.81% |
2021 Q2 | 12.56 Million EUR | 93.07% |
2021 Q3 | 8.75 Million EUR | -30.34% |
2020 Q4 | 7.91 Million EUR | 43.41% |
2020 Q1 | 6.62 Million EUR | -5.96% |
2020 Q3 | 5.52 Million EUR | -39.26% |
2020 Q2 | 9.08 Million EUR | 37.27% |
2020 FY | 13.94 Million EUR | -11.1% |
2019 Q1 | 3.5 Million EUR | -14.62% |
2019 FY | 15.68 Million EUR | 13.14% |
2019 Q4 | 7.04 Million EUR | 70.07% |
2019 Q3 | 4.13 Million EUR | -32.33% |
2019 Q2 | 6.11 Million EUR | 74.77% |
2018 Q3 | 4.09 Million EUR | 46.62% |
2018 Q2 | 2.79 Million EUR | -2.98% |
2018 Q1 | 2.88 Million EUR | 22.61% |
2018 FY | 13.86 Million EUR | 39.9% |
2018 Q4 | 4.09 Million EUR | 0.0% |
2017 Q2 | 1.72 Million EUR | 0.0% |
2017 Q3 | 2.35 Million EUR | 36.5% |
2017 Q4 | 2.35 Million EUR | 0.0% |
2017 FY | 9.9 Million EUR | 24.77% |
2017 Q1 | 1.72 Million EUR | -18.37% |
2016 Q4 | 2.1 Million EUR | 0.0% |
2016 Q3 | 2.1 Million EUR | 13.97% |
2016 Q1 | 1.85 Million EUR | 7.68% |
2016 FY | 7.94 Million EUR | 156.26% |
2016 Q2 | 1.85 Million EUR | 0.0% |
2015 Q1 | 811 Thousand EUR | 323.13% |
2015 Q2 | 811 Thousand EUR | 0.0% |
2015 Q4 | 1.71 Million EUR | 0.0% |
2015 FY | 3.09 Million EUR | 359.78% |
2015 Q3 | 1.71 Million EUR | 111.96% |
2014 Q4 | 191.66 Thousand EUR | 0.0% |
2014 Q2 | 163.21 Thousand EUR | -0.0% |
2014 Q1 | 163.21 Thousand EUR | 0.0% |
2014 FY | 673.97 Thousand EUR | 35.25% |
2014 Q3 | 191.66 Thousand EUR | 17.43% |
2013 FY | 498.32 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -243.141% |
ABIVAX Société Anonyme | 127.37 Million EUR | 88.747% |
Adocia SA | 15.62 Million EUR | 8.292% |
Aelis Farma SA | 18.81 Million EUR | 23.838% |
Advicenne S.A. | 8.21 Million EUR | -74.474% |
genOway Société anonyme | 16.73 Million EUR | 14.37% |
IntegraGen SA | 5.35 Million EUR | -167.781% |
Medesis Pharma S.A. | 1.56 Million EUR | -816.097% |
Neovacs S.A. | 10.34 Million EUR | -38.57% |
NFL Biosciences SA | 4.37 Million EUR | -227.66% |
Plant Advanced Technologies SA | 2.76 Million EUR | -418.401% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -734.301% |
Sensorion SA | 27.05 Million EUR | 47.02% |
Theranexus Société Anonyme | 3 Million EUR | -376.974% |
TME Pharma N.V. | 5.49 Million EUR | -160.742% |
Valbiotis SA | 9.86 Million EUR | -45.233% |
TheraVet SA | 1.64 Million EUR | -771.671% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 29.464% |
DBV Technologies S.A. | 89.4 Million EUR | 83.969% |
Genfit S.A. | 54.8 Million EUR | 73.847% |
GeNeuro SA | 14.35 Million EUR | 0.169% |
Innate Pharma S.A. | 64.57 Million EUR | 77.802% |
Inventiva S.A. | 120.18 Million EUR | 88.074% |
MaaT Pharma SA | 21.59 Million EUR | 33.637% |
MedinCell S.A. | 32.92 Million EUR | 56.464% |
Nanobiotix S.A. | 58.92 Million EUR | 75.677% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 39.239% |
Poxel S.A. | 28.76 Million EUR | 50.172% |
GenSight Biologics S.A. | 32.66 Million EUR | 56.115% |
Transgene SA | 31.23 Million EUR | 54.106% |
Valneva SE | 134.92 Million EUR | 89.377% |